In July 2010, I posted an article with news of study being done on a new genetic test to differentiate between aggressive and nonaggressive types of prostate cancer.
Finally, on May 8, 2013, that test became available to physicians and their patients. Results have shown that the test, developed in collaboration with UCSF and Cleveland Clinic, strongly predicts disease aggressiveness, providing critical information beyond the PSA and the biopsy Gleason Score.
This first of its kind multigene test, using a prostate needle biopsy sample, provides the opportunity for low risk patients to confidently avoid invasive treatments and for high risk patients to make the difficult decision to proceed aggressively with prostate surgery or radiation.
The video below and this press release from Genomic Health offer additional information for those interested.